Market Size of Anemia Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 7.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Anemia Treatment Market Analysis
Over the next few years, the anemia treatment market is expected to register a CAGR of 7.3%.
COVID-19 had an impact on the market's demand-supply balance as well as labor, raw material, and container shortages in addition to its health effects. The supply chain crisis impacted the healthcare industry, including the market for anemia treatment globally, due to inflation and constraints in the supply chain. However, in post-COVID-19 infection patients, the prevalence of anemia is estimated to be high. For instance, the study by Georgia State University in August 2022 evaluated the prevalence of anemia and reported that individuals diagnosed with diabetes, cancer, and anemia pre-COVID are at increased risk of post-COVID anemia. Additionally, the likelihood of post-COVID anemia was significantly higher in people who identified as black or African American, particularly in the outpatient (non-severe COVID-19) population. As a result, with a high prevalence of anemia following COVID-19 infection, there was expected to be a high demand for anemia treatment, which is expected to have a significant impact on the market over the forecast period.
The anemia treatment market is expected to witness robust growth over the forecast period, which is majorly attributed to the increasing cases of anemia across the globe, increasing pipelines for anemia drugs, and an increasing number of women of reproductive age. As per the National Family Health Survey, India, published in February 2022, the prevalence of anemia among six groups in 2021 was 25.0% in men (15-49 years) and 57.0% in women (15-49 years), 31.1% in adolescent boys (15-19 years), 59.1% in adolescent girls, 52.2% in pregnant women (15-49 years), and 67.1% in children (6-59 months). Hence, the survey revealed a high burden of anemia, which is expected to raise the demand for anemia treatment and drive the growth of the market over the study period.
Furthermore, studies for the effective treatment of anemia are still going on and are expected to get more approvals in the market and help the market grow. For instance, as per the JASN phase-3 study report in April 2022, Roxadustat effectively increased hemoglobin in patients with dialysis-dependent chronic kidney disease, with an adverse event profile comparable to that of epoetin alfa. Thus, the new studies reveal the efficacy and safety profile of various products used for anemia treatment and help the market grow over the forecast period. However, the lack of treatment awareness in developing regions, as well as the high cost of drugs, are expected to stifle the growth of the anemia treatment market.
Anemia Treatment Industry Segmentation
As per the scope of the report, anemia is a condition that occurs when the quantity of red blood cells (RBCs) or hemoglobin concentration within them is lower than usual. Hemoglobin is required to transport oxygen, and if the patient has too few or malformed RBCs or not enough hemoglobin, the blood's capacity to transport oxygen to the body's tissues will be reduced. The anemia treatment market is segmented by disease type (iron deficiency anemia, chronic kidney disease anemia, sickle cell anemia, aplastic anemia, and others) and geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type of Disease | |
| Iron Deficiency Anemia | |
| CKD (Chronic Kidney Disease) Anemia | |
| Sickle Cell Anemia | |
| Aplastic Anemia | |
| Other Diseases |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Anemia Treatment Market Size Summary
The anemia treatment market is poised for significant growth, driven by the increasing global prevalence of anemia and the rising number of women of reproductive age. The market is experiencing a resurgence in demand due to the high prevalence of post-COVID-19 anemia, particularly among individuals with pre-existing conditions such as diabetes and cancer. This demand is further bolstered by ongoing research and development efforts, which are expected to yield new drug approvals and enhance treatment options. Despite challenges such as high drug costs and limited awareness in developing regions, the market is supported by the introduction of novel formulations and strategic initiatives to improve access to treatments like intravenous iron drugs.
North America, with the United States as a key contributor, is expected to have a substantial impact on the anemia treatment market. The region's market growth is fueled by a strong pipeline of clinical trials and the presence of major market players. The increasing incidence of chronic conditions such as chronic kidney disease and sickle cell anemia further drives the demand for anemia treatments. Competitive dynamics in the market are characterized by the presence of several companies focused on developing effective therapies, navigating stringent regulatory environments. Recent approvals and product launches, such as Sanofi's Enjaymo and CSL Vifor's Ferinject, highlight the ongoing innovation and expansion in the market, promising to meet the growing demand for anemia treatment solutions.
Anemia Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increasing Cases of Anemia Across the Globe
-
1.2.2 Increasing Number of Women With Reproductive Age
-
-
1.3 Market Restraints
-
1.3.1 Lack of Awareness 糖心vlog传媒 the Treatment in Developing Regions
-
1.3.2 High Cost of Drugs
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Type of Disease
-
2.1.1 Iron Deficiency Anemia
-
2.1.2 CKD (Chronic Kidney Disease) Anemia
-
2.1.3 Sickle Cell Anemia
-
2.1.4 Aplastic Anemia
-
2.1.5 Other Diseases
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Mexico
-
-
2.2.2 Europe
-
2.2.2.1 Germany
-
2.2.2.2 United Kingdom
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Rest of Europe
-
-
2.2.3 Asia-Pacific
-
2.2.3.1 China
-
2.2.3.2 Japan
-
2.2.3.3 India
-
2.2.3.4 Australia
-
2.2.3.5 South Korea
-
2.2.3.6 Rest of Asia-Pacific
-
-
2.2.4 Middle East and Africa
-
2.2.4.1 GCC
-
2.2.4.2 South Africa
-
2.2.4.3 Rest of Middle East and Africa
-
-
2.2.5 South America
-
2.2.5.1 Brazil
-
2.2.5.2 Argentina
-
2.2.5.3 Rest of South America
-
-
-
Anemia Treatment Market Size FAQs
What is the current Anemia Treatment Market size?
The Anemia Treatment Market is projected to register a CAGR of 7.30% during the forecast period (2024-2029)
Who are the key players in Anemia Treatment Market?
Sanofi, AbbVie Inc. (Allergan Plc), Pharmacosmos A/S, Covis Pharma GmbH (AMAG Pharmaceuticals, Inc.) and Pfizer Inc. (Global Blood Therapeutics, Inc.) are the major companies operating in the Anemia Treatment Market.
